In conclusion, this study provides a practical tool for cardiovascular risk assessment in elderly RRMM patients receiving carfilzomib-based therapy, highlighting the importance of Alb levels, hypertension, renal function, and CAD. This evidence concerns the gene ALB and hypertensive disorder.